title: Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain.
abstract: Chest pain experienced by patients with coronary artery disease can be partly due to gastroesophageal reflux-induced chest pain (GERP). Empirical proton pump inhibitor (PPI) therapy has been recommended as an initial clinical approach for treating GERP. However, PPI use may lead to some health problems. The Gastroesophageal Reflux Disease Questionnaire (GerdQ) may represent a noninvasive and cost-effective approach for avoiding PPI misuse and for identifying the appropriate patients for the PPI trial test. The aim of this pilot study was to prospectively evaluate the association between GerdQ scores and PPI response in patients with coronary artery disease (CAD) and GERP to determine whether the GerdQ predicts the PPI response in patients with CAD and GERP and to further validate the clinical application value of the GerdQ. A total of 154 consecutive patients with potential GERP were recruited to complete a GerdQ with subsequent PPI therapy. Based on the PPI trial result, patients were divided into a PPI-positive response group and a PPI-negative response group. The difference in the GerdQ scores between the two groups was assessed. The receiver operating characteristic (ROC) curve of GerdQ score was drawn according to the PPI response as the gold standard. The ability of GerdQ to predict the PPI response was assessed. A total of 96 patients completed the entire study; 62 patients (64.6%) were assigned to the PPI-positive response group, and 34 patients (35.4%) to the PPI-negative response group. The GerdQ score of the PPI-positive response group (8.11 ± 3.315) was significantly higher than that of the PPI-negative response group (4.41 ± 2.743), and the difference was statistically significant (t = 5.863, P = 0.000). The ROC curve was drawn according to a PPI response assessment result with a score above 2 as the gold standard. The area under curve was 0.806. When the critical value of GerdQ score was 7.5, Youden index was up to 0.514, the diagnostic sensitivity was 0.661, and the diagnostic specificity was 0.853. A GerdQ score greater than 7.5 better predicts the response to the PPI trial therapy. There is a strong association between the GerdQ score and the response to PPI therapy. Higher GerdQ scores were predictive of a positive PPI response in CAD patients with GERP. The GerdQ may be a reasonable screening tool for GERP in patients with CAD who are prepared to accept PPI therapy.
authors.affiliation: Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, China.
authors.forename: S
authors.initials: S
authors.lastname: He
authors.affiliation: Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Tang
authors.affiliation: Department of Gastroenterology, Suining Central Hospital, Suining, Sichuan, China.
authors.forename: J
authors.initials: J
authors.lastname: Xu
authors.affiliation: Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China.
authors.forename: C
authors.initials: C
authors.lastname: Tang
mesh_terms: D000328:Adult; D000368:Aged; D002637:Chest Pain / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D003324:Coronary Artery Disease / Q000150:complications*; D016903:Drug Monitoring / Q000379:methods; D050782:Esophageal pH Monitoring / Q000379:methods; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D057240:Patient Preference; D011237:Predictive Value of Tests; D011379:Prognosis; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012372:ROC Curve; D011795:Surveys and Questionnaires
chemical_list: D054328:Proton Pump Inhibitors
keywords: Gastroesophageal Reflux Disease Questionnaire; coronary artery disease; gastroesophageal reflux; noncardiac chest pain; proton pump inhibitor